{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-047916","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.727681+00:00","generated_at":"2026-06-05T11:53:25.992335+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Viridian reports $645.7M cash, $237.7M net loss; VRDN-001 Phase 3 readouts mid-2024","bullets":["Cash, cash equivalents and short-term investments ~$645.7M as of Jan 31, 2024 (preliminary), extending runway into H2 2026.","Net loss for FY2023 was $237.7M vs $129.9M in 2022; R&D expenses rose to $159.8M.","VRDN-001 Phase 3 THRIVE topline data expected mid-2024; THRIVE-2 at year-end 2024.","VRDN-003 subcutaneous pivotal program expected to start mid-2024 pending regulatory alignment.","FcRn inhibitor VRDN-006 IND submission anticipated by year-end 2024; VRDN-008 NHP data H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-047916","json":"https://secwatch.observer/filing/0001193125-24-047916.json","markdown":"https://secwatch.observer/filing/0001193125-24-047916.md","text":"https://secwatch.observer/filing/0001193125-24-047916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524047916/0001193125-24-047916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524047916/d802648d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T11:53:25.992335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d3907d59f1f3647c8b5f38e50f0c51457ccf18d6","claim":"Viridian Therapeutics, Inc.\\DE reported preliminary financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"Viridian Therapeutics, Inc. (the “Company”) issued a press release reporting financial results for the fourth quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524047916/0001193125-24-047916-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}